Education
About Us
Working with TipRanks
Follow Us
Cidara Therapeutics Inc. (CDTX)
:CDTX
CDTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.14 - $66.95
Previous CloseN/A
Volume155.01K
Average Volume (3M)890.09K
Market Cap
$1.37B
Enterprise Value$133.57M
Total Cash (Recent Filing)$168.15M
Total Debt (Recent Filing)$2.67M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Nov 06, 2025EPS Estimate
-1.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding22,117,550
10 Day Avg. Volume386,838
30 Day Avg. Volume890,094
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.10
Enterprise Value/Revenue442.29
Enterprise Value/Gross Profit545.19
Enterprise Value/Ebitda-1.24
Forecast
1Y Price Target
$65.83Price Target Upside6.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCDTX announced positive topline results from the CD388 Ph2b Flu trial, meeting its primary endpoint for all dose levels with statistical significance.
Market ImpactThe positive results from the trial exceeded expectations and are significant for the stock, as they demonstrate better efficacy compared to flu vaccines.
Sales PotentialCD388 has potential for peak sales exceeding $1.5 billion in the U.S. for immunocompromised patients, according to estimates.
Bears Say
Market PositioningThe focus on addressable patient populations and pricing during the earnings call suggests strategic positioning challenges for CD388 in the market.
Regulatory UncertaintyThe company's recent regulatory discussions with the FDA could signal important updates and potential changes to the trial's statistical analysis plan.
Cidara Therapeutics News
CDTX FAQ
What was Cidara Therapeutics Inc.’s price range in the past 12 months?
Cidara Therapeutics Inc. lowest stock price was $10.14 and its highest was $66.94 in the past 12 months.
What is Cidara Therapeutics Inc.’s market cap?
Cidara Therapeutics Inc.’s market cap is $1.37B.
When is Cidara Therapeutics Inc.’s upcoming earnings report date?
Cidara Therapeutics Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.
How were Cidara Therapeutics Inc.’s earnings last quarter?
Cidara Therapeutics Inc. released its earnings results on Aug 07, 2025. The company reported -$1.65 earnings per share for the quarter, beating the consensus estimate of -$1.94 by $0.29.
Is Cidara Therapeutics Inc. overvalued?
According to Wall Street analysts Cidara Therapeutics Inc.’s price is currently Undervalued.
Does Cidara Therapeutics Inc. pay dividends?
Cidara Therapeutics Inc. does not currently pay dividends.
What is Cidara Therapeutics Inc.’s EPS estimate?
Cidara Therapeutics Inc.’s EPS estimate is -1.86.
How many shares outstanding does Cidara Therapeutics Inc. have?
Cidara Therapeutics Inc. has 22,117,550 shares outstanding.
What happened to Cidara Therapeutics Inc.’s price movement after its last earnings report?
Cidara Therapeutics Inc. reported an EPS of -$1.65 in its last earnings report, beating expectations of -$1.94. Following the earnings report the stock price went down -2.715%.
Which hedge fund is a major shareholder of Cidara Therapeutics Inc.?
Currently, no hedge funds are holding shares in CDTX
Cidara Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.83 (6.57% Upside)
$65.83 (6.57% Upside)
Blogger Sentiment
Bullish
CDTX Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $100.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 14.3%
Last 30 Days ▲ 14.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
428.85%
12-Months-Change
Fundamentals
Return on Equity
-299.58%
Trailing 12-Months
Asset Growth
263.70%
Trailing 12-Months
Company Description
Cidara Therapeutics Inc.
Cidara Therapeutics (CDTX) is a biotechnology company specializing in the development of long-acting therapeutics designed to improve the standard of care for patients facing serious fungal or viral infections. The company is focused primarily on leveraging its proprietary Cloudbreak platform to create drug candidates in the areas of infectious disease and oncology. Its lead product candidates include rezafungin, an antifungal agent, and several antiviral conjugates.
CDTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call emphasizes significant progress in the development of CD388, demonstrating promising results in early trials and advancing to a phase 2b study. There is optimism around the potential phase 3 study and the commercial opportunity, highlighted by the planned R&D day. However, the company's current non-revenue generating status and challenges with the NAVIGATE study's design and dose-dependent efficacy present notable concerns.View all CDTX earnings summariesCDTX Stock 12 Month Forecast
Average Price Target
$65.83
▲(6.57% Upside)
Technical Analysis
Ocugen
―
Corvus Pharmaceuticals
―
iTeos Therapeutics
―
Foghorn Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
17.91% Insiders
2.54% Mutual Funds
34.63% Other Institutional Investors
38.91% Public Companies and
Individual Investors